Desvenlafaxine PCD Pharma Franchise Company
Cafoli Lifecare offers a Desvenlafaxine range of 2 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving psychiatry and neurology prescribers can secure district-wise monopoly franchise rights for this SNRI antidepressant with full promotional support.
What is Desvenlafaxine?
Desvenlafaxine is a serotonin-noradrenaline reuptake inhibitor (SNRI) and the active metabolite of venlafaxine. It raises levels of serotonin and noradrenaline in the brain to relieve depression, with convenient once-daily extended-release dosing. Reference: PubChem - Desvenlafaxine.
Available Forms
The Cafoli Desvenlafaxine portfolio is offered as oral extended-release Tablets in the commonly prescribed strengths (50mg, 100mg). Contact us for current pack presentations and trade offers.
Therapeutic Applications
Desvenlafaxine is prescribed for major depressive disorder and is also used in anxiety and menopausal vasomotor symptoms. Prescribers include psychiatrists, neurologists and physicians managing mood disorders.
Why Desvenlafaxine is a High-Potential Molecule for Distributors
Mental-health awareness and treatment rates are rising sharply in India, expanding the antidepressant market, and SNRIs like desvenlafaxine are widely chosen for their once-daily dosing and tolerability. As a chronic, months-to-years therapy prescribed by a loyal specialist base, it delivers dependable long-term refill volume in a growing segment.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Desvenlafaxine
- MedlinePlus: Desvenlafaxine
- PubMed: desvenlafaxine in depression
Our formulations of Desvenlafaxine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: